ArticleEuropean journal of pediatrics2026
Allergy burden score and lung function impairment in children with asthma: a dose-response cross-sectional study.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Children with asthma commonly present with multiple allergic comorbidities; however, the quantitative dose-response relationship between cumulative allergic burden and lung function has not been established in pediatric populations. This retrospective cross-sectional study included 264 treatment-naive children with asthma aged 4-16 years. An allergy burden score (ABS) was constructed using a cumulative disease count strategy incorporating allergic rhinitis, atopic dermatitis, food allergy, drug allergy, and family history of allergic disease. Multivariable linear regression and restricted cubic spline (RCS) analyses assessed dose-response relationships between ABS and FEV
conclusionA dose-response association exists between cumulative allergic comorbidity burden and lung function impairment in treatment-naive children with asthma. Peripheral type 2 inflammatory markers explain only a small proportion of this association, suggesting additional contributing mechanisms. The ABS may warrant further evaluation as a simple clinical indicator for identifying children with greater lung function impairment, pending prospective multicenter validation.
trial registrationNot applicable. As a retrospective cross-sectional study, this research analyzed existing medical records without prospective assignment of interventions by the research team, and therefore does not meet the WHO criteria for clinical trial registration. WHAT IS KNOWN: • Allergic comorbidities are prevalent in children with asthma and associated with worse clinical outcomes. The quantitative dose-response relationship between cumulative allergic burden and lung function has not been established in pediatric populations. WHAT IS NEW: • Each 1-point increase in the Allergy Burden Score (ABS) was associated with a 3.03% decrease in FEV1% predicted, with a nonlinear threshold effect at ABS ≥ 3. Type 2 inflammatory markers collectively accounted for only 2.7% of the total association, suggesting that mechanisms beyond peripheral type 2 inflammation may be involved.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.